To: John Pitera who wrote (2489 ) 10/17/2001 1:29:06 PM From: John Pitera Respond to of 2850 INTC and IBM earnings: Tuesday After Hours price changes vs 4pm ET levels: On the heels of the closing bell, IBM (IBM 106 +4.15) got things rolling, having reported a Q3 profit of $0.90 per share that was a penny better than the consensus estimate. Revenues of $20.4 bln, though, came up a bit short of the First Call consensus estimate of $20.8 bln (Multex consensus $20.92 bln). On its call, IBM said Q4 will be challenging, but that the current EPS estimate for Q4 is reasonable (First Call consensus is $1.35)... Intel (INTC 25.45 +0.49) reported an in-line profit of $0.10 per share for Q3 on revenues of $6.5 bln that were ahead of the Multex consensus estimate of $6.389 bln, and its own expectation that revenues would be just below the mid-point of the $6.2-$6.8 bln range the company originally provided. Looking ahead, Intel provided the same revenue range for Q4, and that has tempered investor enthusiasm as it implies little, if any, sequential growth in what is traditionally the company's strongest quarter; related stocks include AMD, CPQ and DELL... Veritas Software (VRTS 31.99 +2.56) has been gaining ground after hours following a reassuring earnings report and an admission that it remains comfortable with Wall Street's expectations for Q4 (First Call consensus is profit of $0.13 per share and revenues of $356 mln; Multex consensus is $0.14 and revenues of $368.47 mln); related stocks include CA, EMC, HWP, IBM, CPQ, MSFT and SUNW... Rambus (RMBS 12.50 +0.78) is also on the move after it reported a fiscal Q4 net of $0.06 per share, $0.02 ahead of estimates, and announced a share buyback of up to 5 mln shares... Finally, Eli Lilly (LLY 73.75 -5.25) is getting knocked around after an FDA advisory panel split 10-10 on whether to recommend approval of the company's sepsis drug Xigris; a panel recommendation in favor of this key drug had been expected... For more detail on these, and other developments, be sure to visit Briefing.com's In Play, Earnings Calendar, and Guidance pages. Presently, the S&P futures, at 1104, are 4 points above fair value while the Nasdaq 100 futures, at 1427, are 16 points above fair value.-- Patrick J. O'Hare, Briefing.com 18:02 ET ****** IBM (IBM) 101.85 -0.15: Apparently, Barry Bonds was not the only giant delivering in September. Big Blue allayed many fears in its conference call after the bell by reaffirming Q4 EPS guidance. Many analysts had expected the company to guide down, however, many analysts had already taken down Q3 and Q4 estimates over the past couple of weeks. Nevertheless, IBM posted a solid quarter in a difficult environment. Also, it gained market share in three important areas in Q3: services, high end servers and software. IBM truly is an integrated solutions provider. Its diversification attracts customers as it provides a one stop shopping experience with a well capitalized company you know will be around. But it also spreads risk so that one weak area will not hurt profits too much. With IT spending in the condition it's in, it would be tough to argue against its business model....PC sales continued to weaken for IBM, although it had little impact on profits. In fact, overall gross margin increased this quarter to 36.2%, up 80 bp over last year....Bottom line: Company reaffirmed EPS guidance for Q4 and said if GDP improves as it expects next year, IT spending should increase 10%. We're a bit disappointed that Q4 revenue guidance and all 2002 guidance was omitted. However, considering that many had expected a substantial warning for Q4, this report was about as good as anyone could have expected. -- Robert J. Reid, Briefing.com